Novo Nordisk submits obesity drug for FDA approval

Semaglutide will also be used as a treatment for obesity, according to Novo Nordisk's plan – the pharmaceutical giant has submitted an application to the FDA in the US.
Photo: Stine Tidsvilde
Photo: Stine Tidsvilde

Within the next six months, Novo Nordisk will find out whether its drug semaglutide can be used as a treatment for obesity, aside from its use as a drug against diabetes in US patients.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading